Literature DB >> 19996657

Elevated blood active ghrelin and unaltered total ghrelin and obestatin concentrations in prostate carcinoma.

Witold Malendowicz1, Agnieszka Ziolkowska, Marta Szyszka, Zbigniew Kwias.   

Abstract

PURPOSE: Ghrelin and its functional receptor are highly expressed in prostate cancer (PC) and ghrelin may activate proliferation of PC cell lines. This study was therefore designed to characterize the association between serum acylated and total ghrelin, and obestatin levels in patients with benign prostate hyperplasia (BPH) and PC.
METHODS: Blood serum concentrations of active and total ghrelin and obestatin were estimated by EIA methods.
RESULTS: Serum level of active ghrelin in PC was significantly higher compared to control and BPH groups. On the other hand, concentrations of total ghrelin and of obestatin did not differ between studied groups of patients. In the control group the ratio of active to total ghrelin concentrations amounted to 0.16, and it was similar in BPH (0.14), while it was notably elevated in PC (0.42). Also the ratio of active ghrelin to obestatin concentrations was higher in the group with PC than in the control and BPH groups. In all studied groups, the ratio of total circulating ghrelin to obestatin was similar.
CONCLUSIONS: Obtained results suggest the link between elevated blood active ghrelin and PC, and we cannot exclude that elevated circulating active ghrelin may affect growth of malignant prostatic tissues. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996657     DOI: 10.1159/000251190

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  10 in total

Review 1.  Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?

Authors:  Mark D DeBoer
Journal:  Mol Cell Endocrinol       Date:  2011-02-25       Impact factor: 4.102

Review 2.  The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism.

Authors:  Mark D DeBoer
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Authors:  Tomofumi Miura; Shuichi Mitsunaga; Masafumi Ikeda; Izumi Ohno; Hideaki Takahashi; Hidetaka Suzuki; Ai Irisawa; Takeshi Kuwata; Atsushi Ochiai
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

4.  Randomized trial of weight loss on circulating ghrelin levels among breast cancer survivors.

Authors:  Leah Puklin; Brenda Cartmel; Maura Harrigan; Lingeng Lu; Fang-Yong Li; Tara Sanft; Melinda L Irwin
Journal:  NPJ Breast Cancer       Date:  2021-05-11

Review 5.  Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review.

Authors:  Sakine Sever; Donna L White; José M Garcia
Journal:  Endocr Relat Cancer       Date:  2016-09       Impact factor: 5.678

Review 6.  Ghrelin and Breast Cancer: Emerging Roles in Obesity, Estrogen Regulation, and Cancer.

Authors:  CheukMan Cherie Au; John B Furness; Kristy A Brown
Journal:  Front Oncol       Date:  2017-01-09       Impact factor: 6.244

7.  Circulating adipokines and metabolic setting in differentiated thyroid cancer.

Authors:  Chiara Mele; Maria Teresa Samà; Alessandro Angelo Bisoffi; Marina Caputo; Valentina Bullara; Stefania Mai; Gillian Elisabeth Walker; Flavia Prodam; Paolo Marzullo; Gianluca Aimaretti; Loredana Pagano
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 8.  Attribution of Ghrelin to Cancer; Attempts to Unravel an Apparent Controversy.

Authors:  Saeed Soleyman-Jahi; Fatemeh Sadeghi; Amin Pastaki Khoshbin; Leila Khani; Venus Roosta; Kazem Zendehdel
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

9.  High-Fat Diet Induced Gut Microbiota Alterations Associating With Ghrelin/Jak2/Stat3 Up-Regulation to Promote Benign Prostatic Hyperplasia Development.

Authors:  Meng Gu; Chong Liu; TianYe Yang; Ming Zhan; Zhikang Cai; Yanbo Chen; Qi Chen; Zhong Wang
Journal:  Front Cell Dev Biol       Date:  2021-06-24

10.  No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.

Authors:  Michelle L Maugham; Inge Seim; Patrick B Thomas; Gabrielle J Crisp; Esha T Shah; Adrian C Herington; Kristy A Brown; Laura S Gregory; Colleen C Nelson; Penny L Jeffery; Lisa K Chopin
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.